Biogen Erases Gains After Analysts Raise Price Targets

Stock Markets28 minutes ago (Jun 11, 2021 10:37AM ET)

(C) Reuters.

By Dhirendra Tripathi – Biogen (NASDAQ:BIIB) shares fell close to 2% Friday despite analysts raising their price targets after the Food and Drug Administration’s decision to approve the company’s Alzheimer’s drug.

The biotech company’s aducanumab is the first Alzheimer’s medicine in 18 years to secure the FDA nod, which came Monday (NASDAQ:MNDY).

Bernstein and JPMorgan (NYSE:JPM) raised their price targets on potential sales from the drug.

Bernstein’s outperform rating sees the Biogen stock at $500, an upside of 22% from the stock’s current level of $410.

According to analyst Aaron Gal, market circumstance will allow for strong adoption of Biogen’s ‘aduhelm’ and that regulatory scrutiny of the price of the new Alzheimer’s drug will come later.

He sees aduhelm sales reaching $10 billion in 2023, with conservative assumptions.

Biogen will charge $56,000 for an annual course, a price drawing much criticism from advocacy groups.

JPMorgan analyst Cory Kasimov raised Biogen’s target price to $435 while maintaining a neutral rating.

Biogen Erases Gains After Analysts Raise Price Targets

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Stories


Popular Categories